Medicine and Dentistry
Apoplexy
100%
Randomized Controlled Trial
85%
Multiple Sclerosis
60%
Thigh
60%
Deep Vein Thrombosis
50%
Placebo
42%
Riluzole
32%
Fluoxetine
32%
Amiloride
32%
Neuroprotective Agent
26%
Arm
22%
Diet Supplementation
20%
Thrombosis Prevention
20%
Hospital Inpatient
20%
Brain Growth
20%
Physical Disability
20%
Cognitive Reserve
20%
Lifespan
20%
Percutaneous Endoscopic Gastrostomy
17%
Expanded Disability Status Scale
17%
Magnetic Resonance Imaging
15%
Venous Thromboembolism
15%
Hazard Ratio
10%
Treatment Group
7%
Proportional Hazards Model
7%
Nutrition Supplement
6%
Adverse Event
6%
Quality of Life
5%
Functional Status
5%
Neuroscience
Secondary Progressive Multiple Sclerosis
40%
Multiple Sclerosis
26%
Placebo
25%
Expanded Disability Status Scale
24%
Fluoxetine
20%
Riluzole
20%
Cerebrovascular Accident
20%
Randomized Controlled Trial
20%
Amiloride
20%
Magnetic Resonance Imaging
11%
Neuroprotective Agent
9%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Sclerosis
40%
Placebo
40%
Amiloride
32%
Riluzole
32%
Fluoxetine
32%
Neuroprotective Agent
24%
Randomized Controlled Trial
20%
Expanded Disability Status Scale
8%
Adverse Event
6%
